LINDA MCCRACKEN: Open Payments
NPI 1780307850 · NEW WILMINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,814 in 157 payments from 20 companies in 2025. Trend: 2023 $2,303 · 2024 $2,839 · 2025 $2,814
Food & beverage: $2,804Education: $10
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 17 | $327 |
| ABBVIE INC. | 25 | $326 |
| AstraZeneca Pharmaceuticals LP | 11 | $293 |
| Novo Nordisk Inc | 15 | $282 |
| Lilly USA, LLC | 17 | $252 |
| Lundbeck LLC | 13 | $247 |
| Otsuka America Pharmaceutical, Inc. | 10 | $222 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 13 | $177 |
| PFIZER INC. | 9 | $177 |
| Amgen Inc. | 9 | $161 |
Products named: REXULTI, TRELEGY ELLIPTA, MOUNJARO, Ozempic, FARXIGA, ELIQUIS, JARDIANCE, QULIPTA.
Industry payments across PA — which companies pay providers there.
